États-Unis · Plateformes & données · MarketBeat

Freenome Q3 Earnings Call Highlights

Publié par MarketBeat · États-Unis il y a 34 min

Image from MarketBeat Media, LLC. · MarketBeat

Résumé détaillé

Freenome (NASDAQ:FRNM) reported third-quarter revenue of $183.5 million, driven largely by revenue recognition following the U.S. Food and Drug Administration’s approval of its blood-based colorectal cancer screening test. The company said it does not expect meaningful testing revenue or royalties i

Lire l'article complet sur MarketBeat Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.marketbeat.com)

Freenome Q3 Earnings Call Highlights

Résumé détaillé

À lire aussi

Sonos expects $570M-$630M Q1 revenue as it targets 500 bps gross margin uplift by FY27 exit

‘The thought of living to 100 terrifies me’: Is Social Security a giant Ponzi scheme?

Prediction: This Will Be AMD’s Stock Price After 1 Year

Five US states join FTC suit against Hims & Hers over privacy practices

SLS Stock Rises After-Hours: State Street Reveals Over 5% Stake — And One Fund Manager Boosted Holdings By Nearly 1,000%

Fed Governor Waller sees December hike likely, opens door to possible half-point increase

Freenome Q3 Earnings Call Highlights

Résumé détaillé

Partager

À lire aussi

Sonos expects $570M-$630M Q1 revenue as it targets 500 bps gross margin uplift by FY27 exit

‘The thought of living to 100 terrifies me’: Is Social Security a giant Ponzi scheme?

Prediction: This Will Be AMD’s Stock Price After 1 Year

Five US states join FTC suit against Hims & Hers over privacy practices

SLS Stock Rises After-Hours: State Street Reveals Over 5% Stake — And One Fund Manager Boosted Holdings By Nearly 1,000%

Fed Governor Waller sees December hike likely, opens door to possible half-point increase